Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes.

doi:10.1200/JCO.20.02341

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 10 May 2021

Sallman David A, DeZern Amy E, Garcia-Manero Guillermo, Steensma David P, Roboz Gail J, Sekeres Mikkael A, Cluzeau Thomas, Sweet Kendra L, McLemore Amy, McGraw Kathy L, Puskas John, Zhang Ling, Yao Jiqiang, Mo Qianxing, Nardelli Lisa, Al Ali Najla H, Padron Eric, Korbel Greg, Attar Eyal C, Kantarjian Hagop M, Lancet Jeffrey E, Fenaux Pierre, List Alan F, Komrokji Rami S

Abstract excerpt

PURPOSE: Approximately 20% of patients with TP53-mutant myelodysplastic syndromes (MDS) achieve complete remission (CR) with hypomethylating agents. Eprenetapopt (APR-246) is a novel, first-in-class, small molecule that restores wild-type p53 functions in TP53-mutant cells. METHODS: This was a phase Ib/II study to determine the safety, recommended phase II dose, and efficacy of eprenetapopt administered in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aged, 80 and over

Share to Antineoplastic Combined Chemotherapy Protocols

Share to Azacitidine

Share to Biomarkers, Tumor

Share to Mutation

Share to Myelodysplastic Syndromes

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 33449813
DOI: 10.1200/JCO.20.02341
PMCID: PMC8099410

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes.PMID 33449813Read ↗

Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM).Semantic proximity Read ↗

Personalized Medicine for TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia.Semantic proximity Read ↗

TP53-mutated acute myeloid leukemia and myelodysplastic syndrome: biology, treatment challenges, and upcoming approaches.Semantic proximity Read ↗

Targeting TP53 Mutations in Myelodysplastic Syndromes.Semantic proximity Read ↗

TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Current Guidelines, Therapies, and Future Considerations.Semantic proximity Read ↗

CPX-351 selectively benefits patients with AML and myelodysplasia-related mutations in the pivotal randomized trial.Semantic proximity Read ↗

TP53 Mutations in Acute Leukemias and Myelodysplastic Syndromes: Insights and Treatment Updates.Semantic proximity Read ↗

XPO1 drives resistance to eprenetapopt and azacitidine and can be targeted in TP53 -mutated myeloid malignanciesSemantic proximity Read ↗

To target the untargetable: elucidation of synergy of APR-246 and azacitidine in TP53 mutant myelodysplastic syndromes and acute myeloid leukemiaSemantic proximity Read ↗

TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions.Semantic proximity Read ↗

Managing the unmanageable: evidence-driven approaches to real-world patient prototypes of TP53-mutant myelodysplastic neoplasms and acute myeloid leukemia.Semantic proximity Read ↗

Molecular Characterization and Clinical Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Patients With TP53 Mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.